• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FutureTech II Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    11/10/25 9:50:39 PM ET
    $FTII
    Blank Checks
    Finance
    Get the next $FTII alert in real time by email
    false 0001889450 0001889450 2025-11-08 2025-11-08 0001889450 us-gaap:CommonStockMember 2025-11-08 2025-11-08 0001889450 us-gaap:RightsMember 2025-11-08 2025-11-08 0001889450 FTII:UnitsMember 2025-11-08 2025-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    November 8, 2025

    Date of Report (Date of earliest event reported)

     

    FutureTech II Acquisition Corp.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-41289   87-2551539
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    128 Gail Drive

    New Rochelle, NY

      10805
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (914) 316-4805

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

     

    Securities registered pursuant to Section 12(b) of the Act: None

     

    Securities registered pursuant to Section 12(g) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   FTII    
    Rights   FTIIW    
    Units   FTIIU    

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.02. Termination of Material Definitive Agreement.

     

    As previously disclosed, on April 7, 2025, FutureTech II Acquisition Corp. (the “Company”) executed six Zero Interest Convertible Notes, dated April 4, 2025 and April 7, 2025 (each, a “Convertible Note,” and collectively, the “Convertible Notes”), that were issued to Wuhao Zhang, Yujie Zhou, Wanrong Wang, Shouxiang Lu, Ji Wang and Gang Yuan (each, an “Investor,” and collectively, the “Investors”). Pursuant to the Convertible Notes, among other things, the Investors agreed to loan the Company $1,025,000 in aggregate principal (the “Principal Amount”) in exchange for their right to convert all or any part of the Principal Amount and any accrued interest (the “Conversion Amount”) into the shares of the Company at or any time after the closing of the initial business combination by the Company. The maturity date of the Convertible Notes was September 30, 2025 (the “Maturity Date”). The Convertible Notes are interest-free, except that if there are no conversions or no repayments of the Principal Amount on the Maturity Date and the Maturity Date is extended, an interest of five percent (5%) per annum will apply to the Principal Amount commencing from the Maturity Date, calculated on a 365 day/year basis. No monies were paid to the Company by the Investors pursuant to the Convertible Notes.

     

    On November 8, 2025, the Company signed a termination agreement (each, a “Termination Agreement,” and collectively, the “Termination Agreements”) with each Investor, pursuant to which the Convertible Notes with each Investor were terminated effective as of November 8, 2025, and of no further force and effect.

     

    The foregoing description of the Termination Agreements is only a summary and does not purport to be complete and are qualified in their entirety by reference to the full text of the Termination Agreements, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (c) Exhibits.

     

    The following exhibits are filed as part of, or incorporated by reference into, this Report.

     

    No.   Description of Exhibit
    10.1*   Termination Agreements, dated as of November 8, 2025, by and between FutureTech II Acquisition Corp. and the Investors
    104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

    * Filed herewith.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FUTURETECH II ACQUISITION CORP.
    Dated: November 10, 2025    
      By: /s/ Ray Chen
      Name: Ray Chen
      Title: Chief Executive Officer

     

    3

     

    Get the next $FTII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FTII
    SEC Filings

    View All

    SEC Form RW filed by FutureTech II Acquisition Corp.

    RW - FutureTech II Acquisition Corp. (0001889450) (Filer)

    11/26/25 5:21:57 PM ET
    $FTII
    Blank Checks
    Finance

    SEC Form NT 10-Q filed by FutureTech II Acquisition Corp.

    NT 10-Q - FutureTech II Acquisition Corp. (0001889450) (Filer)

    11/14/25 5:29:13 PM ET
    $FTII
    Blank Checks
    Finance

    FutureTech II Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - FutureTech II Acquisition Corp. (0001889450) (Filer)

    11/10/25 9:50:39 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & CFO Chen Ray Lei converted options into 380,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 8:42:18 PM ET
    $FTII
    Blank Checks
    Finance

    Large owner Radu Zachary C. converted options into 2,445,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 6:30:25 PM ET
    $FTII
    Blank Checks
    Finance

    Director Bush Neil converted options into 10,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 4:48:44 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance

    New York, New York, Dec. 04, 2024 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (the "Company") (NASDAQ:FTII), today announced that it received an expected deficiency notification letter from the staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on November 27, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the "SEC") on November 15, 2024. Th

    12/4/24 1:35:00 PM ET
    $FTII
    Blank Checks
    Finance

    Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity

     -Longevity Biomedical, Inc. is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase the health span for the rapidly growing global aging population.    -Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.    -Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, and Phase 2 start for LBI-001 in retinal vein occlusion.    -Seasoned management team of m

    9/20/24 2:55:00 PM ET
    $FTII
    Blank Checks
    Finance

    FutureTech II Acquisition Corp. Confirms Funding and Extension of Period to Complete Initial Business Combination

    New Rochelle, NY, May 17, 2023 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (NASDAQ:FTIIU) (the "Company"), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, announced today that it caused to be deposited $1,150,000 into the Company's trust account for its public stockholders, representing $0.10 per public share, allowing the Company to extend by three months (from May 18, 2023 to August 18, 2023) the period of time the Company has to consummate its initial business combination (the "Extension"). The Extension is the second of two

    5/17/23 4:05:00 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FutureTech II Acquisition Corp.

    SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/14/24 1:07:48 PM ET
    $FTII
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by FutureTech II Acquisition Corp.

    SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/13/24 4:51:36 PM ET
    $FTII
    Blank Checks
    Finance

    SEC Form SC 13G filed by FutureTech II Acquisition Corp.

    SC 13G - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/13/24 4:41:47 PM ET
    $FTII
    Blank Checks
    Finance